
## Siegbert Rieg

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1193957/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Pre-medication with oral anticoagulants is associated with better outcomes in a large multinational COVID-19 cohort with cardiovascular comorbidities. Clinical Research in Cardiology, 2022, 111, 322-332.	3.3	9
2	Antimicrobial Stewardship with and without Infectious Diseases Specialist Services to Improve Quality-of-Care in Secondary and Tertiary Care Hospitals in Germany: Study Protocol of the ID ROLL OUT Study. Infectious Diseases and Therapy, 2022, 11, 617-628.	4.0	1
3	Impact of neutropenia on clinical manifestations and outcome of Staphylococcus aureus bloodstream infection: a propensity score-based overlap weight analysis in two large, prospectively evaluated cohorts. Clinical Microbiology and Infection, 2022, 28, 1149.e1-1149.e9.	6.0	2
4	SARS-CoV-2-specific T-cell epitope repertoire in convalescent and mRNA-vaccinated individuals. Nature Microbiology, 2022, 7, 675-679.	13.3	29
5	Closing Sexual Health Service Caps With a New Service Model in Germany: Performance of an on-Site Integrated, Cross-Sectoral, Low Threshold Sexually Transmitted Infections/HIV Counseling and Treatment Service. Frontiers in Public Health, 2022, 10, 793609.	2.7	1
6	Early and Rapid Identification of COVID-19 Patients with Neutralizing Type I Interferon Auto-antibodies. Journal of Clinical Immunology, 2022, 42, 1111-1129.	3.8	17
7	Elevated markers of thrombo-inflammatory activation predict outcome in patients with cardiovascular comorbidities and COVID-19 disease: insights from the LEOSS registry. Clinical Research in Cardiology, 2021, 110, 1029-1040.	3.3	19
8	Characterization of pre-existing and induced SARS-CoV-2-specific CD8+ T cells. Nature Medicine, 2021, 27, 78-85.	30.7	295
9	Outcomes of <scp>SARSâ€CoVâ€2</scp> Infections in Patients with Neurodegenerative Diseases in the <scp>LEOSS</scp> Cohort. Movement Disorders, 2021, 36, 791-793.	3.9	13
10	Clinical course and predictive risk factors for fatal outcome of SARS-CoV-2 infection in patients with chronic kidney disease. Infection, 2021, 49, 725-737.	4.7	14
11	Impact of Immunosuppressive Agents on Clinical Manifestations and Outcome of <i>Staphylococcus aureus</i> Bloodstream Infection: A Propensity Score–Matched Analysis in 2 Large, Prospectively Evaluated Cohorts. Clinical Infectious Diseases, 2021, 73, 1239-1247.	5.8	4
12	Validation of an internationally derived patient severity phenotype to support COVID-19 analytics from electronic health record data. Journal of the American Medical Informatics Association: JAMIA, 2021, 28, 1411-1420.	4.4	37
13	Influence of immunosuppression in patients with severe acute respiratory distress syndrome on venoâ€venous extracorporeal membrane oxygenation therapy. Artificial Organs, 2021, 45, 1050-1060.	1.9	11
14	Therapy with lopinavir/ritonavir and hydroxychloroquine is associated with acute kidney injury in COVID-19 patients. PLoS ONE, 2021, 16, e0249760.	2.5	9
15	International Analysis of Electronic Health Records of Children and Youth Hospitalized With COVID-19 Infection in 6 Countries. JAMA Network Open, 2021, 4, e2112596.	5.9	33
16	Prediction of COVID-19 deterioration in high-risk patients at diagnosis: an early warning score for advanced COVID-19 developed by machine learning. Infection, 2021, , 1.	4.7	18
17	Rapid and stable mobilization of CD8+ T cells by SARS-CoV-2 mRNA vaccine. Nature, 2021, 597, 268-273.	27.8	279
18	Anti–platelet factor 4 antibodies causing VITT do not cross-react with SARS-CoV-2 spike protein. Blood, 2021, 138, 1269-1277.	1.4	102

#	Article	IF	CITATIONS
19	Development and validation of a simplified risk score for the prediction of critical COVIDâ€19 illness in newly diagnosed patients. Journal of Medical Virology, 2021, 93, 6703-6713.	5.0	6
20	Reducing burden from respiratory infections in refugees and immigrants: a systematic review of interventions in OECD, EU, EEA and EU-applicant countries. BMC Infectious Diseases, 2021, 21, 872.	2.9	3
21	Specific Risk Factors for Fatal Outcome in Critically Ill COVID-19 Patients: Results from a European Multicenter Study. Journal of Clinical Medicine, 2021, 10, 3855.	2.4	12
22	Neurological symptoms and complications in predominantly hospitalized COVIDâ€19 patients: Results of the European multinational Lean European Open Survey on SARSâ€Infected Patients (LEOSS). European Journal of Neurology, 2021, 28, 3925-3937.	3.3	25
23	First results of the "Lean European Open Survey on SARS-CoV-2-Infected Patients (LEOSS)― Infection, 2021, 49, 63-73.	4.7	62
24	Serum Protein Profiling Reveals a Specific Upregulation of the Immunomodulatory Protein Progranulin in Coronavirus Disease 2019. Journal of Infectious Diseases, 2021, 223, 775-784.	4.0	21
25	Multinational characterization of neurological phenotypes in patients hospitalized with COVID-19. Scientific Reports, 2021, 11, 20238.	3.3	10
26	Angiotensin II receptor blocker intake associates with reduced markers of inflammatory activation and decreased mortality in patients with cardiovascular comorbidities and COVID-19 disease. PLoS ONE, 2021, 16, e0258684.	2.5	5
27	Enterococcus faecalis bloodstream infection: does infectious disease specialist consultation make a difference?. Infection, 2021, 49, 1289-1297.	4.7	5
28	Within-host evolution of SARS-CoV-2 in an immunosuppressed COVID-19 patient as a source of immune escape variants. Nature Communications, 2021, 12, 6405.	12.8	128
29	Complement system component dysregulation is a distinctive feature of COVID-19 disease: a prospective and comparative analysis of patients admitted to the emergency department for suspected COVID-19 disease. Journal of Thrombosis and Thrombolysis, 2021, , 1.	2.1	6
30	Machine Learning Based Prediction of COVID-19 Mortality Suggests Repositioning of Anticancer Drug for Treating Severe Cases. Artificial Intelligence in the Life Sciences, 2021, 1, 100020.	2.2	6
31	Covidâ€19 in patients with hematological and solid cancers at a Comprehensive Cancer Center in Germany. Cancer Medicine, 2020, 9, 8412-8422.	2.8	29
32	Comparison of different anticoagulation strategies for renal replacement therapy in critically ill patients with COVID-19: a cohort study. BMC Nephrology, 2020, 21, 486.	1.8	20
33	Vancomycin-resistant Enterococcus faecium colonizing patients on hospital admission in Germany: prevalence and molecular epidemiology. Journal of Antimicrobial Chemotherapy, 2020, 75, 2743-2751.	3.0	23
34	Defining persistent Staphylococcus aureus bacteraemia: secondary analysis of a prospective cohort study. Lancet Infectious Diseases, The, 2020, 20, 1409-1417.	9.1	84
35	Combination therapy with rifampicin or fosfomycin in patients with Staphylococcus aureus bloodstream infection at high risk for complications or relapse: results of a large prospective observational cohort. Journal of Antimicrobial Chemotherapy, 2020, 75, 2282-2290.	3.0	10
36	A Single-Center Prospective Cohort Study on Postsplenectomy Sepsis and its Prevention. Open Forum Infectious Diseases, 2020, 7, ofaa050.	0.9	8

#	Article	IF	CITATIONS
37	Staphylococcus aureus Bloodstream Infection in Patients with Atopic Dermatitis, or: Think Twice Before Placing a Venous Catheter into Lesional Atopic Skin. Journal of Investigative Dermatology, 2020, 140, 1870-1872.	0.7	3
38	Protocol update for the SABATO trial: a randomized controlled trial to assess early oral switch therapy in low-risk Staphylococcus aureus bloodstream infection. Trials, 2020, 21, 175.	1.6	9
39	Infectious disease consultation for candidaemia. Lancet Infectious Diseases, The, 2020, 20, 164-165.	9.1	2
40	Prevention of post-splenectomy sepsis in patients with asplenia - a study protocol of a controlled trial. BMC Infectious Diseases, 2020, 20, 41.	2.9	5
41	COVID-19 in-hospital mortality and mode of death in a dynamic and non-restricted tertiary care model in Germany. PLoS ONE, 2020, 15, e0242127.	2.5	47
42	Title is missing!. , 2020, 15, e0242127.		0
43	Title is missing!. , 2020, 15, e0242127.		0
44	Title is missing!. , 2020, 15, e0242127.		0
45	Title is missing!. , 2020, 15, e0242127.		0
46	Infectious disease services: a survey from four university hospitals in Germany. Infection, 2019, 47, 27-33.	4.7	8
47	Effect of Clinically Uninfected Orthopedic Implants and Pacemakers/AICDs in Low-Risk Staphylococcus aureus Bloodstream Infection on Crude Mortality Rate: A Post Hoc Analysis of a Large Cohort Study. Open Forum Infectious Diseases, 2019, 6, ofz170.	0.9	9
48	Extracorporeal membrane oxygenation in Pneumocystis jirovecii pneumonia: outcome in HIV and non-HIV patients. Critical Care, 2019, 23, 356.	5.8	15
49	Investigating the Impact of Early Valve Surgery on Survival in Staphylococcus aureus Infective Endocarditis Using a Marginal Structural Model Approach: Results of a Large, Prospectively Evaluated Cohort. Clinical Infectious Diseases, 2019, 69, 487-494.	5.8	6
50	Screening for Infectious Diseases on Arrival and Integrated Healthcare for Refugees and Asylum Seekers During the First Months After Arrival. Migration, Minorities and Modernity, 2019, , 75-85.	0.0	0
51	Management of superficial and deep-seated Staphylococcus aureus skin and soft tissue infections in sub-Saharan Africa: a post hoc analysis of the StaphNet cohort. Infection, 2018, 46, 395-404.	4.7	7
52	Survival following Staphylococcus aureus bloodstream infection: A prospective multinational cohort study assessing the impact of place of care. Journal of Infection, 2018, 77, 516-525.	3.3	48
53	Staphylococcus aureus bloodstream infection in patients with ventricular assist devices–Management and outcome in a prospective bicenter cohort. Journal of Infection, 2018, 77, 30-37.	3.3	8
54	Rifampicin in treating S aureus bacteraemia. Lancet, The, 2018, 392, 554-555.	13.7	5

#	Article	IF	CITATIONS
55	Case Report and Genetic Sequence Analysis of <i>Candidatus</i> Borrelia kalaharica, Southern Africa. Emerging Infectious Diseases, 2018, 24, 1659-1664.	4.3	9
56	Staphylococcus aureus bacteremia in patients with rheumatoid arthritis – Data from the prospective INSTINCT cohort. Journal of Infection, 2017, 74, 575-584.	3.3	13
57	Determining vancomycin Etest MICs in patients with MRSA bloodstream infection does not support switching antimicrobials. Journal of Infection, 2017, 74, 248-259.	3.3	10
58	Whipple's disease mimicking rheumatoid arthritis can cause misdiagnosis and treatment failure. Orphanet Journal of Rare Diseases, 2017, 12, 99.	2.7	30
59	Five cases of vector-borne Francisella tularensis holarctica infections in south-western Germany and genetic diversity. Ticks and Tick-borne Diseases, 2017, 8, 808-812.	2.7	17
60	Combination antimicrobial therapy in patients with Staphylococcus aureus bacteraemia—a post hoc analysis in 964 prospectively evaluated patients. Clinical Microbiology and Infection, 2017, 23, 406.e1-406.e8.	6.0	49
61	Staphylococcus aureus bacteremia with iliac artery endarteritis in a patient receiving ustekinumab. BMC Infectious Diseases, 2016, 16, 586.	2.9	8
62	Infectious diseases consultations can make the difference: a brief review and a plea for more infectious diseases specialists in Germany. Infection, 2016, 44, 159-166.	4.7	50
63	Differential induction of innate defense antimicrobial peptides in primary nasal epithelial cells upon stimulation with inflammatory cytokines, Th17 cytokines or bacterial conditioned medium from Staphylococcus aureus isolates. Microbial Pathogenesis, 2016, 90, 69-77.	2.9	10
64	Intestinal decolonization of Enterobacteriaceae producing extended-spectrum β-lactamases (ESBL): a retrospective observational study in patients at risk for infection and a brief review of the literature. BMC Infectious Diseases, 2015, 15, 475.	2.9	42
65	Polymorphisms in Fibronectin Binding Proteins A and B among Staphylococcus aureus Bloodstream Isolates Are Not Associated with Arthroplasty Infection. PLoS ONE, 2015, 10, e0141436.	2.5	10
66	Early oral switch therapy in low-risk Staphylococcus aureus bloodstream infection (SABATO): study protocol for a randomized controlled trial. Trials, 2015, 16, 450.	1.6	42
67	Amino acid alterations in fibronectin binding protein A (FnBPA) and bacterial genotype are associated with cardiac device related infection in Staphylococcus aureus bacteraemia. Journal of Infection, 2015, 70, 153-159.	3.3	18
68	The innate defense antimicrobial peptides hBD3 and RNase7 are induced in human umbilical vein endothelial cells by classical inflammatory cytokines but not Th17 cytokines. Microbes and Infection, 2015, 17, 353-359.	1.9	15
69	S2kâ€Leitlinie* "Diagnostik und Therapie der Syphilis" – Kurzfassung S2k guideline* "Diagnosis and therapy of syphilis―—―short version. JDDG - Journal of the German Society of Dermatology, 2015, 13, 472-481.	0.8	2
70	Staphylococcus aureus bloodstream infection: A pooled analysis of five prospective, observational studies. Journal of Infection, 2014, 68, 242-251.	3.3	207
71	Expression of the sweat-derived innate defence antimicrobial peptide dermcidin is not impaired in <i>Staphylococcus aureus</i> colonization or recurrent skin infections. Clinical and Experimental Dermatology, 2014, 39, 209-212.	1.3	7
72	Adherence to an antibiotic stewardship bundle targeting Staphylococcus aureus blood stream infections at a 200-bed community hospital. Infection, 2014, 42, 713-719.	4.7	56

#	Article	IF	CITATIONS
73	Differential time to positivity is not predictive for central line-related Staphylococcus aureus bloodstream infection in routine clinical care. Journal of Infection, 2014, 68, 58-61.	3.3	36
74	Reply to Krause etÂal Journal of Infection, 2014, 69, 294-295.	3.3	1
75	Staphylococcal disease in Africa: another neglected â€~tropical' disease. Future Microbiology, 2013, 8, 17-26.	2.0	26
76	Acute fibrinous and organizing pneumonia associated with influenza A/H1N1 pneumonia after lung transplantation. BMC Pulmonary Medicine, 2013, 13, 30.	2.0	37
77	Microarray-Based Genotyping and Clinical Outcomes of Staphylococcus aureus Bloodstream Infection: An Exploratory Study. PLoS ONE, 2013, 8, e71259.	2.5	25
78	Expression of innate defense antimicrobial peptides in hidradenitis suppurativa. Journal of the American Academy of Dermatology, 2012, 66, 966-974.	1.2	65
79	Fatal hemophagocytic syndrome in a patient with a previously well-controlled asymptomatic HIV infection after EBV reactivation. Journal of Infection, 2012, 64, 110-112.	3.3	14
80	Tick-borne lymphadenopathy (TIBOLA) acquired in Southwestern Germany. BMC Infectious Diseases, 2011, 11, 167.	2.9	37
81	Susceptibility of clinical Staphylococcus aureus isolates to innate defense antimicrobial peptides. Microbes and Infection, 2011, 13, 761-765.	1.9	5
82	Use of a Simple Criteria Set for Guiding Echocardiography in Nosocomial Staphylococcus aureus Bacteremia. Clinical Infectious Diseases, 2011, 53, 1-9.	5.8	128
83	Differential activity of innate defense antimicrobial peptides against Nocardia species. BMC Microbiology, 2010, 10, 61.	3.3	18
84	<i>Paenibacillus larvae</i> Bacteremia in Injection Drug Users. Emerging Infectious Diseases, 2010, 16, 487-489.	4.3	31
85	Myelodysplastic syndrome with complex karyotype associated with longâ€ŧerm highly active antiretroviral therapy. British Journal of Haematology, 2009, 145, 670-673.	2.5	9
86	Mortality of S. aureus bacteremia and infectious diseases specialist consultation – A study of 521 patients in Germany. Journal of Infection, 2009, 59, 232-239.	3.3	165
87	Resistance against antimicrobial peptides is independent of Escherichia coli AcrAB, Pseudomonas aeruginosa MexAB and Staphylococcus aureus NorA efflux pumps. International Journal of Antimicrobial Agents, 2009, 33, 174-176.	2.5	37
88	Quiz Page June 2007. American Journal of Kidney Diseases, 2007, 49, A49-A50.	1.9	7
89	Generation of Multiple Stable Dermcidin-Derived Antimicrobial Peptides in Sweat of Different Body Sites. Journal of Investigative Dermatology, 2006, 126, 354-365.	0.7	75
90	Deficiency of Dermcidin-Derived Antimicrobial Peptides in Sweat of Patients with Atopic Dermatitis Correlates with an Impaired Innate Defense of Human Skin In Vivo. Journal of Immunology, 2005, 174, 8003-8010.	0.8	248